In parallel, PD-1 and PD-L1 have been the most successfully used immunotherapy targets, and antibodies targeting PD-1 and PD-L1 have exhibited promising efficacy in melanoma, lung carcinoma, and renal-cell cancer [12, 13]. Here, PDCD1 is linked to renal cell adenocarcinoma.